References
- Guay DR. (2006). Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson’s disease. Am J Geriatr Pharmacother 4:330–46
- Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. (2007). Rasagiline – a novel MAO-B inhibitor in Parkinson’s disease therapy. Ther Clin Risk Manag 3:467–74
- Sterling J, Veinberg A, Lerner D. (1998). A controlled trial of rasagiline in early Parkinson disease. J Neural Transm Suppl 52:301–5
- Thébault JJ, Guillaume M, Levy R. (2004). Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 24:1295–305
- van der Laan JW, Brightwell J, McAnulty P. (2010). Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. J Pharmacol Toxicol Methods 62:184–95
- Youdim MBH, Gross A, Finberg JPM. (2001). Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132:500–6